Neoleukin emerges with a de novo approach to improving biologics

Why Neoleukin is making biologics from scratch rather than fine-tuning existing ones

With a platform to design proteins from scratch, Neoleukin is making a new class of biologics that resemble their endogenous protein counterparts in structure, but not in sequence. The strategy gives the company a clean slate to improve function and reduce toxicity without the constraints built in by nature.

A spinout of David Baker’s lab at University of Washington’s Institute for Protein Design, the company debuted in January with a Nature paper describing a de novo IL-2 protein that resembled the endogenous cytokine in 3-D structure, but had a different amino acid sequence and better preclinical efficacy and toxicity in mouse models of melanoma or colon cancer.

Baker is director of University of Washington’s Institute for

Read the full 1147 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE